SynthesisBMC anesthesiology2025
Remimazolam compared to dexmedetomidine on the incidence of hypotension in middle aged and elderly patients undergoing general anesthesia: a systematic review and meta-analysis.
Synthesis in BMC anesthesiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundThe objective of this study is to compare the effects of remimazolam and dexmedetomidine on the incidence of hypotension in middle-aged and elderly patients undergoing general anesthesia, and to evaluate the safety profiles of both medications.
methodsWe systematically searched PubMed, Cochrane Library, EMBASE, and Web of Science from inception to July 2024 for randomized controlled trials comparing remimazolam versus dexmedetomidine in patients aged ≥ 45 years undergoing general anesthesia. Two investigators independently screened studies, extracted data, and assessed risk of bias using the Cochrane RoB 2 tool. Meta-analyses employed random-effects models to calculate risk ratios (RR) with 95% confidence intervals. The primary outcome was intraoperative hypotension incidence; secondary outcomes included bradycardia, tachycardia, hypertension, and postoperative nausea and vomiting.
resultsThis meta-analysis included 8 randomized controlled trials with 741 patients (384 remimazolam; 357 dexmedetomidine). There was no statistically significant difference in intraoperative hypotension between groups (RR 0.78, 95% CI 0.36-1.68, P = 0.53, I²=71%). Remimazolam showed a significant reduction in bradycardia risk compared to dexmedetomidine (RR 0.41, 95% CI 0.23-0.73, P = 0.002, I²=0%). However, remimazolam had a higher risk of tachycardia (RR 3.41, 95% CI 1.47-7.90, P = 0.004, I²=0%). There was no significant difference in intraoperative hypertension (RR 0.85, 95% CI 0.38-1.90, P = 0.69, I²=0%) or postoperative nausea and vomiting(RR 0.98, 95% CI 0.30-3.23, P = 0.97, I²=0%).
conclusionsRemimazolam and dexmedetomidine did not differ significantly in intraoperative hypotension, intraoperative hypertension, or postoperative nausea and vomiting in middle-aged and elderly patients. Remimazolam reduced the incidence of bradycardia. In contrast, dexmedetomidine had an advantage in reducing intraoperative tachycardia. These findings support individualized anesthetic selection based on patients' specific cardiovascular risk profiles.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.